630 W GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Market cap: $2.1B (2/10/2026)
Price: $36.59
GUIDES TO OVER $1 BILLION IN WAKIX® REVENUE IN 2026; ADVANCING ROBUST LATE-STAGE PIPELINE WITH POTENTIAL FOR LONG-TERM VALUE CREATION
Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
Preannounces Strong Q3 2025 Wakix Performance; Raises 2025 Revenue Guidance
Provides Update From Its Phase 3 RECONNECT Study Of ZYN002 In Fragile X Syndrome
Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data from Phase 3 Registrational Trial in Q3 2025
Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025
STRENGTHENS PATENT POSITION WITH FAVORABLE SETTLEMENT IN ANDA LITIGATION
Shareholder votes
Q3
Q2
Q1
FY 2023
FY 2023 amended
Registration Statement for Securities to be Offered to Employees
S-3ASR
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence
Prospectus filed pursuant to Rule 424(b)(7)